BTIG Rates Verastem (VSTM) buy, $18 Price Target

BTIG reaffirms its positive outlook on Verastem with an $18 price target, a 421.74% upside from the current price.

By EarningsIQ Research Desk · Published Jun 24, 2026, 7:02 AM EDT · Updated Jun 26, 2026, 11:03 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Verastem, Inc. ($VSTM) "buy" with a $18 price target on June 24, 2026.

Since the rating, $VSTM is up 6.5% after 1 week, up 57.1% after 1 month and up 124.7% to date (from the $3.85 close on Jun 24, 2026).

VSTM Verastem, Inc.

$8.65 +19.64% year to date

Daily close · Oct 16, 2026

Key Points

BTIG reiterated its buy rating for Verastem, Inc. (VSTM) with a price target of $18 on June 24, 2026.
BTIG's $18 price target implies 421.74% upside from Verastem, Inc.'s ($VSTM) current $3.45 share price.
Verastem shares traded at $4.21 on Wednesday, with a market cap of about $373.5 million and a 52-week range between $3.55 and $11.25.
Insiders, including Michael Bailey, bought shares recently, and major funds like BlackRock increased their stakes.

Get $VSTM trade alerts by text

We text you when insiders, Congress or big funds trade $VSTM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Verastem, Inc. alert may contain errors. Disclosures

BTIG has reiterated its buy rating on Verastem, Inc. (NasdaqCM: VSTM), maintaining a price target of $18. This reaffirmation came on June 24, 2026, as analyst Jeet Mukherjee expressed continued confidence in the company's prospects.

Analyst rating track record

BTIG vs. the S&P 500

YTD return -18.83% hypothetical

All-time return +32.91% S&P 500 +38.56%

vs. S&P 500 -5.65% behind the index

Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Verastem, Inc.

Several major funds have been active in Verastem recently. BlackRock, Inc. added 1,442,083 shares, increasing its holdings by 30.3% to 6,194,925 shares, valued at about $32.8 million. Armistice Capital, LLC also increased its stake by 1,056,000 shares, a 29.9% boost, ending with 4,592,000 shares worth approximately $24.3 million. Nantahala Capital Management, LLC made a significant move, growing its position by 3,122,680 shares, a 675.7% increase, to hold 3,584,820 shares valued at $19 million.

Verastem, Inc. Stock Down 53.6%

Shares of Verastem, Inc. traded near $4.21 on Wednesday. The company has a market capitalization of about $373.5 million. Despite a negative forward P/E ratio due to unprofitability, the stock's beta is relatively low at 0.267, indicating less volatility. Its 52-week range spans from $3.55 to $11.25, with a 50-day moving average of $4.90 and a 200-day moving average of $7.04. The company's current ratio is 3.035, and its debt-to-equity ratio stands at 104.522.

12-month forecast

$VSTM price target

Verastem, Inc. daily closes and this analyst's $18 target. Not advice.

Recent Earnings

Verastem reported revenue of $49.6 million, although it has not yet achieved profitability, as reflected by its negative return on equity of -7.86%. The company did not generate a net margin in the recent period. Investors are looking forward to the next earnings release, scheduled for August 6, 2026.

Insider Buying and Selling at Verastem, Inc.

On May 21, 2026, several insiders, including Michael Bailey, Karin Anna Tollefson, Anil Kapur, Eric Rowinsky, Brian Stuglik, and John Johnson, each bought 36,000 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 24, 2026, BTIG reiterated its buy rating with an $18 price target. Jefferies maintained its buy rating on June 23, 2026, with an $8 target. Mizuho also kept a buy rating with a $14 target on May 14, 2026. Overall, the consensus among eight analysts is a strong buy, with a mean price target of $16.

About Verastem, Inc.

Verastem, Inc. is a biopharmaceutical company based in Needham, Massachusetts. It focuses on developing and commercializing cancer therapies. Its lead product candidates include Avutometinib and Defactinib, targeting various cancer pathways. The company collaborates with major players like Pfizer and Amgen to enhance its drug development efforts. Verastem was founded in 2010 and employs around 102 people.

Bottom Line

BTIG's reiterated buy rating reflects its confidence in Verastem's potential, with an ambitious $18 price target. The company's ongoing collaborations and active insider buying suggest a commitment to advancing its cancer treatment pipeline. As always, investors should remember that analyst ratings are one of many factors to consider when evaluating a stock.